509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study

Molinier, O.; Falchero, L.; Monnet, I.; Decroisette, C.; Neidhart, A-C.; Redureau, E.; Chiappa, A.M.; Bigot, F.; Bedossa, A.; Amrane, Karim; Jeandeau, S.; Dujon, C.; Bugnet, A-S.; Bonnefoy, P.; Alizon, C.; Meyer, N.; Couraud, S.; Cortot, A.; Letierce, A.; Debieuvre, D.

doi:10.1016/j.annonc.2022.07.637

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We considered that collecting COVID-19 diagnoses from the hospital medical records would not be reliable, as most reported cases were based on external samples without systematic transcription into patient records. Additionally, infections were rare at that time, and their prognosis among LC patients was already known and published [26,30,31].…”

Section: Discussionmentioning

confidence: 99%

A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial)

Molinier,

Guguen,

Marcq

et al. 2023

Cancers

View full text Add to dashboard Cite

The consequences of the strict health restrictions during the first wave of COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated the impact of the initial lockdown on management of and long-term outcome in LC patients. This exposed–unexposed-type study included two evaluation periods of 6 months each in non-selected patients; one began on the first day of lockdown in 2020, and the other in 2019 during the same calendar period. Various indicators were compared: clinical profiles, management delays and overall survival beyond 2 years. A total of 816 patients from 7 public or private centers were enrolled. The clinical characteristics of the patients in 2020 did not differ from those in 2019, except that the population was older (p = 0.002) with more non-smokers (p = 0.006). Delays for pre-therapeutic medical management were generally reduced after the first imaging in 2020 (1.28 [1.1–1.49]). In the multivariate analysis, being part of the 2020 cohort was correlated with better prognosis (HR = 0.71 [0.5–0.84], p < 0.001). The gain observed in 2020 mainly benefited non-smoking patients, along with ECOG PS 0–2 (p = 0.01), stage 4 (p = 0.003), squamous cell carcinoma (p = 0.03) and receiving systemic therapy (p = 0.03). In conclusion, the first lockdown did not exert any deleterious impact on LC patients.

show abstract

Section: Discussionmentioning

confidence: 99%